Clinical Trials Logo

Sickle Cell Anemia clinical trials

View clinical trials related to Sickle Cell Anemia.

Filter by:

NCT ID: NCT00294541 Terminated - Sickle Cell Disease Clinical Trials

A Study Evaluating the Long-Term Safety of ICA-17043 in Sickle Cell Disease Patients With or Without Hydroxyurea Therapy

Start date: February 2006
Phase: Phase 3
Study type: Interventional

This trial is a follow-up companion study to Protocol ICA-17043-10, a Phase III, multi-center, efficacy and safety study of ICA-17043. This is an open-label extension study collecting safety data on the use of ICA-17043 in subjects with sickle cell disease (SCD) (e.g., HbSS, HbSC, HbSb0-thalassemia, HbSb+-thalassemia subjects). All subjects who have successfully completed ICA-17043-10 will, if deemed appropriate by their study Investigator and appropriate consent by subject is given, enroll in the ICA-17043-12 study (Study 12). Only patients who participated in ICA-17043-10 are eligible for this open label study

NCT ID: NCT00040469 Terminated - Sickle Cell Anemia Clinical Trials

Bone Marrow Transplant From Related Donor for Patients With High Risk Hemoglobinopathies

Start date: August 2000
Phase: Phase 2
Study type: Interventional

The major goal of this study is to determine the risks and benefits of bone marrow transplants in patients with severe thalassemia or sickle cell disease. Participation in this project will be for two years.

NCT ID: NCT00040417 Terminated - Sickle Cell Anemia Clinical Trials

Bone Marrow Transplant From Donor Using Less Toxic Conditioning for Patient With High Risk Hemoglobinopathies

Start date: August 2000
Phase: Phase 2
Study type: Interventional

The major goal of this study is to determine the risks and benefits of stem cell transplants in combination with a newer, less toxic conditioning chemotherapy treatment in patients with severe sickle cell disease (SCD) or sickle hemoglobin variants (hemoglobin SC or hemoglobin SB0/+), or homozygous b0/+ thalassemia or severe B0/+ thalassemia variants. Participation in this project will be for one year, with follow up evaluations done every 6 months thereafter for 10 years or until participants are 18 years old.